Want to see MMSI full AI Analyst Report?
MMSI Stock Chart & Stats
$74.32
$1.78(2.40%)
At close: 4:00 PM EDT
$74.32
$1.78(2.40%)
Day’s Range― - ―
52-Week Range$59.74 - $94.75
Previous Close$76.1
Volume1.03M
Average Volume (3M)748.57K
Market Cap
$5.42B
Enterprise Value$4.53K
Total Cash (Recent Filing)$448.70M
Total Debt (Recent Filing)$820.12M
Price to Earnings (P/E)37.1
Beta0.58
Next Earnings
Oct 22, 2026EPS Estimate
1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.45
Shares Outstanding59,710,420
10 Day Avg. Volume674,096
30 Day Avg. Volume748,573
Financial Highlights & Ratios
PEG Ratio8.41
Price to Book (P/B)3.29
Price to Sales (P/S)3.44
P/FCF Ratio24.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$99.56Price Target Upside33.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)4.3
Revenue Forecast (FY)$1.64B
Bulls Say, Bears Say
Bulls Say
Broad-based Revenue And Margin ExpansionBroad-based organic growth across foundational and therapeutic products indicates sustained procedure demand and portfolio relevance. Margin expansion shows scale and mix benefits that can support durable earnings growth as revenue increases.
Recurring Disposable-device Business ModelMerit's single-use devices generate repeat demand whenever procedures occur, creating a replenishment-based revenue model. Exposure across cardiology, radiology, oncology and other specialties diversifies utilization and supports customer retention.
Strong Cash Generation And Acquisition CapacityRobust operating and free cash flow provides internal funding for product development, manufacturing investment and acquisitions. Substantial liquidity and borrowing capacity also give Merit flexibility to expand its portfolio without relying solely on equity financing.
Bears Say
Ongoing Tariff ExposureTariffs can raise input and manufacturing costs across the global supply chain, creating a persistent margin risk rather than a single-quarter issue. Passing costs to hospitals may be difficult where contracts and purchasing groups constrain pricing.
Meaningful Leverage RemainsLeverage has improved but remains material, which can limit financial flexibility and increase sensitivity to interest costs or weaker procedure volumes. Debt also raises execution risk if Merit continues using acquisitions to expand its product portfolio.
Portfolio Disruption And Elevated Cost BaseThe divestiture and recall have reduced sales in affected areas and may require time and spending to rebuild account relationships. Meanwhile, faster SG&A and R&D growth can dilute operating leverage if revenue growth moderates.
Merit Medical Systems News
MMSI FAQ
What was Merit Medical’s price range in the past 12 months?
Merit Medical lowest stock price was $59.74 and its highest was $94.75 in the past 12 months.
What is Merit Medical’s market cap?
Merit Medical’s market cap is $5.42B.
When is Merit Medical’s upcoming earnings report date?
Merit Medical’s upcoming earnings report date is Oct 22, 2026 which is in 60 days.
How were Merit Medical’s earnings last quarter?
Merit Medical released its earnings results on Jul 30, 2026. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.959 by $0.231.
Is Merit Medical overvalued?
According to Wall Street analysts Merit Medical’s price is currently Undervalued.
Does Merit Medical pay dividends?
Merit Medical does not currently pay dividends.
What is Merit Medical’s EPS estimate?
Merit Medical’s EPS estimate is 1.04.
How many shares outstanding does Merit Medical have?
Merit Medical has 59,710,420 shares outstanding.
What happened to Merit Medical’s price movement after its last earnings report?
Merit Medical reported an EPS of $1.19 in its last earnings report, beating expectations of $0.959. Following the earnings report the stock price went up 1.992%.
Which hedge fund is a major shareholder of Merit Medical?
Currently, no hedge funds are holding shares in MMSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merit Medical Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$99.56 (33.96% Upside)
$99.56 (33.96% Upside)
Blogger Sentiment
Neutral
MMSI Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 291.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.73%
Trailing 12-Months
Company Description
Merit Medical
Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products. These devices are crucial for a broad spectrum of diagnostic, therapeutic, and interventional procedures, primarily within the fields of cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two main divisions: Cardiovascular and Endoscopy. Its extensive product portfolio includes advanced solutions for diagnosing and treating conditions in peripheral vessels and organs, as well as a comprehensive suite of cardiac intervention products. The latter encompasses tools for vascular access, angiography, electrophysiology, cardiac rhythm management, fluid and hemodynamic monitoring, hemostasis, and various interventional therapies for heart-related ailments. Additionally, MMSI provides customized procedural solutions, offering critical care items, disinfection protection systems, specialized syringes, manifold kits, and tailored trays and packs. Their offerings further extend to coated tubes and wires, alongside sophisticated sensor components for microelectromechanical systems (MEMS). The company also features pulmonary products, such as laser-cut tracheobronchial stents with their accompanying over-the-wire and direct visualization delivery systems, and dilation balloons used for endoscopic stricture dilation. Gastroenterology products, as well as essential kits and accessories for endoscopy and bronchoscopy procedures, complete their diverse catalog. Merit Medical Systems sells its products to a wide client base, including hospitals and healthcare professionals (physicians, technicians, and nurses) working in alternative care settings. Distribution channels include a direct sales force, authorized distributors, original equipment manufacturer (OEM) partnerships, and custom procedure tray manufacturers, reaching customers throughout the United States and internationally. Founded in 1987, Merit Medical Systems, Inc. has its corporate headquarters situated in South Jordan, Utah.
MMSI Company Deck
MMSI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum with above-expectation revenue growth, robust organic expansion, margin improvement and upgraded full-year guidance. Key strategic acquisitions were integrated and commercialized successfully, and cash generation remained healthy. Offsetting items included one-time tariff refunds, ongoing tariff volatility, seasonality into Q3, higher operating expenses, inventory buildup, and some lingering effects from a prior product recall and portfolio divestiture. On balance the positives — broad-based organic growth, margin expansion, upgraded guidance, and successful acquisition execution — materially outweigh the negatives.View all MMSI earnings summariesMMSI Stock 12 Month Forecast
Average Price Target
$99.56
▲(33.96% Upside)
Technical Analysis
ICU Medical
―
Lemaitre Vascular
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
2.65% Insiders
37.77% Mutual Funds
28.52% Other Institutional Investors
5.41% Public Companies and
Individual Investors